Prevail Innovative Wealth Advisors LLC Boosts Position in Johnson & Johnson $JNJ

Prevail Innovative Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 75.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,950 shares of the company’s stock after buying an additional 5,144 shares during the quarter. Prevail Innovative Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,035,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. World Investment Advisors grew its position in shares of Johnson & Johnson by 19.6% in the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after buying an additional 26,450 shares during the last quarter. Benchmark Financial LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $554,000. Principal Financial Group Inc. boosted its stake in Johnson & Johnson by 0.8% in the fourth quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock valued at $705,736,000 after acquiring an additional 28,370 shares in the last quarter. KBC Group NV grew its holdings in Johnson & Johnson by 21.8% in the fourth quarter. KBC Group NV now owns 2,296,831 shares of the company’s stock worth $475,330,000 after purchasing an additional 410,720 shares during the last quarter. Finally, SageGuard Financial Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $1,019,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 48,972 shares of company stock worth $12,295,205 over the last quarter. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $260.74 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company’s fifty day moving average price is $250.68 and its 200-day moving average price is $240.77. Johnson & Johnson has a 1-year low of $172.70 and a 1-year high of $274.90. The firm has a market capitalization of $628.36 billion, a PE ratio of 30.21, a price-to-earnings-growth ratio of 2.48 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter last year, the business posted $2.77 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is 62.11%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research report on Wednesday, July 15th. Barclays upped their target price on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 15th. Bank of America increased their price target on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research note on Friday, July 10th. Weiss Ratings upgraded Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Finally, Scotiabank restated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $268.22.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is advancing seltorexant into late-stage development for major depressive disorder, potentially adding a novel growth opportunity to its Innovative Medicine pipeline. The company also announced a multiyear partnership with ACCESS to expand advanced cardiac electrophysiology technologies in ambulatory surgery centers, supporting its higher-growth MedTech strategy. Johnson & Johnson Advances Seltorexant and Expands Outpatient Cardiac Care
• Positive Sentiment: Recent catalysts include FDA De Novo authorization for the OTTAVA robotic surgery system, Priority Review for RYBREVANT FASPRO and a collaboration on in-vivo CAR-T therapies. These developments strengthen JNJ’s long-term growth narrative beyond its established products. What Johnson & Johnson’s OTTAVA FDA Win and Talc Deal Shift Mean for Shareholders
• Positive Sentiment: JNJ’s latest quarterly results exceeded expectations, with revenue rising 6.6% year over year to $25.31 billion and adjusted earnings per share reaching $2.90. Management raised its full-year 2026 EPS outlook to $11.60-$11.75, reinforcing confidence in the business. Johnson & Johnson vs. Medtronic After Earnings
• Positive Sentiment: JNJ remains attractive to income-focused investors because of its long record of uninterrupted dividend increases, diversified operations and relatively strong balance sheet. Johnson & Johnson vs. AbbVie: Safe Dividend vs. Higher Yield

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.